Additional Relevant Details Lilly, in partnership with Incyte, submitted a NDA for baricitinib in January 2016.  The PDUFA date, although not yet set, is projected to be in early fourth quarter of 2016.  

FDA was initially expected to make a decision in early Q4 of 2016, got delayed 3 months.